AbCellera Biologics Management
Management criteria checks 4/4
AbCellera Biologics' CEO is Carl Hansen, appointed in Nov 2012, has a tenure of 11.58 years. total yearly compensation is $714.94K, comprised of 64.3% salary and 35.7% bonuses, including company stock and options. directly owns 19.24% of the company’s shares, worth $157.88M. The average tenure of the management team and the board of directors is 2.9 years and 4.8 years respectively.
Key information
Carl Hansen
Chief executive officer
US$714.9k
Total compensation
| CEO salary percentage | 64.3% |
| CEO tenure | 11.6yrs |
| CEO ownership | 19.2% |
| Management average tenure | 2.9yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth
May 29
AbCellera: Cash Providing Shelter From Market Weakness
May 16AbCellera: Victim Of Its Own Success
Feb 28AbCellera Biologics: Continuing To Expand Partnerships
Feb 13Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?
Feb 04AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate
Nov 29AbCellera Biologics: Many Reasons To Own This Undervalued Stock
Sep 06AbCellera Biologics: COVID Antibody Set To Provide Continued Funding
Aug 14AbCellera partnering with Atlas Ventures on development of therapeutic antibodies
Aug 03AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying
Jun 06Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)
May 13Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%
May 07AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment
Apr 22AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm
Feb 11AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues
Dec 05AbCellera Biologics: The COVID Premium Is Gone, Thanks To Merck - Time To Buy
Oct 18AbCellera Biologics: I Was Wrong
Aug 20AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Are More Bearish Than They Used To Be
Aug 17AbCellera Biologics: A Buy At Current Prices
Aug 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$147m |
| Dec 31 2023 | US$715k | US$460k | -US$146m |
| Sep 30 2023 | n/a | n/a | -US$129m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$50m |
| Dec 31 2022 | US$9m | US$450k | US$159m |
| Sep 30 2022 | n/a | n/a | US$248m |
| Jun 30 2022 | n/a | n/a | US$200m |
| Mar 31 2022 | n/a | n/a | US$205m |
| Dec 31 2021 | US$9m | US$400k | US$153m |
| Sep 30 2021 | n/a | n/a | US$177m |
| Jun 30 2021 | n/a | n/a | US$197m |
| Mar 31 2021 | n/a | n/a | US$203m |
| Dec 31 2020 | US$17m | US$296k | US$85m |
| Sep 30 2020 | n/a | n/a | -US$285k |
| Jun 30 2020 | n/a | n/a | US$2m |
| Mar 31 2020 | n/a | n/a | -US$3m |
| Dec 31 2019 | US$250k | US$177k | -US$2m |
Compensation vs Market: Carl's total compensation ($USD714.94K) is below average for companies of similar size in the US market ($USD3.43M).
Compensation vs Earnings: Carl's compensation has been consistent with company performance over the past year.
CEO
Carl Hansen (49 yo)
11.6yrs
Tenure
US$714,939
Compensation
Dr. Carl L. G. Hansen, Ph.D. is a Co-Founder of AbCellera Biologics Inc. and has been its Chief Executive Officer and Director since November 2012 and serves as its Chairperson. Dr. Hansen serves as a Memb...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairperson | 11.6yrs | US$714.94k | 19.24% $ 157.9m | |
| Chief Financial Officer | 4.8yrs | US$674.56k | 0.097% $ 792.3k | |
| COO & Director | 5.4yrs | US$650.59k | 3.24% $ 26.6m | |
| Chief Legal Officer | 4.8yrs | US$667.69k | 0.00017% $ 1.4k | |
| Senior Director of Finance & Accounting | no data | no data | no data | |
| Chief Technology Officer | 3.4yrs | no data | no data | |
| Head of Corporate Communications | less than a year | no data | no data | |
| Director of Corporate Development | 1.4yrs | no data | no data | |
| Senior Vice President of Partnering | 1.4yrs | no data | no data | |
| Chief Commercial Officer | 2.4yrs | US$5.61m | 0.016% $ 135.0k | |
| Senior Vice President of Discovery | no data | no data | no data | |
| Site Head & VP of Complex Membrane Protein Technologies | 1.4yrs | no data | no data |
2.9yrs
Average Tenure
49.5yo
Average Age
Experienced Management: ABCL's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairperson | 11.6yrs | US$714.94k | 19.24% $ 157.9m | |
| COO & Director | 5.8yrs | US$650.59k | 3.24% $ 26.6m | |
| Independent Lead Director | 4.8yrs | US$105.00k | 0.49% $ 4.0m | |
| Independent Non-Employee Director | 3.6yrs | US$77.50k | 0.031% $ 253.9k | |
| Independent Director | 2.5yrs | US$55.00k | 0% $ 0 |
4.8yrs
Average Tenure
58yo
Average Age
Experienced Board: ABCL's board of directors are considered experienced (4.8 years average tenure).